Drug Profile
Ferucarbotran - Bayer HealthCare Pharmaceuticals
Alternative Names: BAY 864884; Cliavist; Ferrixan; Resovist; SHU 555A; ZK 132281Latest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals; Bayer Yakuhin; Meito Sangyo
- Class Contrast media; Diagnostic agents; Heavy metals; Imaging agents; Oxides
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Liver cancer
Most Recent Events
- 24 Sep 2013 Discontinued - Preregistration for Liver cancer (diagnosis) in USA (IV)
- 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
- 07 Jul 2010 No development reported - Preregistration for Liver cancer (diagnosis) in USA (IV)